Various A2aR and CD39/CD73 antagonistic therapies have been developed and show encouraging preclinical anti-tumor results warranting the multiple ongoing clinical studies (ClinicalTrials.gov 2019). The gene discussed is ENTPD1; the disease is neoplasm.